Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421353 | 0.83 | — | — | |
| SCHEMBL5997632 | 0.83 | CA12 (0.44) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL145307 | 0.80 | — | — | |
| SCHEMBL28468317 | 0.80 | ALDH1A1 (0.42) | ALDH1A1CYP1A2 | |
| SCHEMBL9079929 | 0.80 | ALDH1A1 (0.42) | ALDH1A1CYP1A2 | |
| SCHEMBL16904 | 0.80 | ALDH1A1 (0.42) | ALDH1A1CYP1A2 | |
| SCHEMBL957418 | 0.78 | ALDH1A1 (0.39) | ALDH1A1CYP1A2ACHE | |
| SCHEMBL31478000 | 0.78 | ALDH1A1 (0.39) | ALDH1A1CYP1A2ACHE | |
| SCHEMBL5430146 | 0.77 | CYP1A2 (0.54) | ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL10787986 | 0.76 | ALDH1A1 (0.40) | ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046712-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2021-06-29 | — | — | US | disclosed |
| EP-3419972-A1 | GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2019-01-02 | — | — | EP | disclosed |
| EP-3419974-A1 | PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES | Asceneuron SA (CH) | 2019-01-02 | — | — | EP | disclosed |
| EP-3419976-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | Asceneuron SA (CH) | 2019-01-02 | — | — | EP | disclosed |
| EP-3419971-A1 | GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2019-01-02 | — | — | EP | disclosed |
| WO-2017144635-A1 | PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144639-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144637-A1 | ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144633-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| EP-3186243-A1 | GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016030443-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2016-03-03 | — | — | WO | disclosed |
| CN-102083312-B | Benzene sulfonamide thiazole and oxazole compounds | SMITHKLINE BEECHAM CORP | 2014-08-27 | — | — | CN | disclosed |
| US-20130053396-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2013-02-28 | — | — | US | disclosed |
| EP-2480543-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. (IT) | 2012-08-01 | — | — | EP | disclosed |
| CN-102083312-A | Benzene sulfonamide thiazole and oxazole compounds | SMITHKLINE BEECHAM CORP | 2011-06-01 | — | — | CN | disclosed |
| WO-2011036478-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2011-03-31 | — | — | WO | disclosed |
| CN-100469780-C | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2009-03-18 | — | — | CN | disclosed |
| CN-1918169-A | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2007-02-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053396-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | SHH, SMO, GLI1 | CA12 2879/4885CA1 2181/4885CA2 3523/4885 |
| US-11046712-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | CA12 498/4885CA1 272/4885CA2 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.